Published • loading... • Updated
Delphi Diagnostics Announces New Publication in the European Journal of Cancer
The study of 659 PACS-01 samples found EAIRR added statistically significant prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score.
- On Wednesday, Delphi Diagnostics announced new clinical data published in the European Journal validating Recurrence Risk as a significant independent predictor of outcomes for hormone receptor-positive, node-positive breast cancer patients.
- The study demonstrates that EAIRR, also known as SET2,3, provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score, enhancing risk stratification for node-positive patients.
- Researchers analyzed 659 patient samples from the PACS-01 clinical trial, establishing Level 1B evidence that EAIRR refines prognostic risk stratification beyond existing assays.
- Data indicate EAI strongly predicted benefit from adjuvant endocrine therapy with interaction values below 0.001, enabling physicians to identify patients sensitive to treatment for personalized care decisions.
- Delphi Diagnostics aims to make the EAI test available to patients, opening pathways for personalized breast cancer treatment, while developer Fraser Symmans maintains a financial relationship with the company managed by the Anderson Cancer Center's Interest Committee.
Insights by Ground AI
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left1Leaning Right1Center10Last UpdatedBias Distribution84% Center
Bias Distribution
- 84% of the sources are Center
84% Center
C 84%
Factuality
To view factuality data please Upgrade to Premium
